CN103167873A - 治疗眼血管疾病的给药方案 - Google Patents

治疗眼血管疾病的给药方案 Download PDF

Info

Publication number
CN103167873A
CN103167873A CN2011800496321A CN201180049632A CN103167873A CN 103167873 A CN103167873 A CN 103167873A CN 2011800496321 A CN2011800496321 A CN 2011800496321A CN 201180049632 A CN201180049632 A CN 201180049632A CN 103167873 A CN103167873 A CN 103167873A
Authority
CN
China
Prior art keywords
vegf
inhibitor
days
administered
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800496321A
Other languages
English (en)
Chinese (zh)
Inventor
M·布里戈尔
P·恩德
V·霍萨格拉哈拉
B·贾菲
E·梅莱迪斯
R·牛顿
S·普尔
Y·邱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103167873A publication Critical patent/CN103167873A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2011800496321A 2010-10-27 2011-10-25 治疗眼血管疾病的给药方案 Pending CN103167873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40721810P 2010-10-27 2010-10-27
US61/407,218 2010-10-27
PCT/EP2011/068682 WO2012055884A1 (en) 2010-10-27 2011-10-25 Dosing regimes for the treatment of ocular vascular disease

Publications (1)

Publication Number Publication Date
CN103167873A true CN103167873A (zh) 2013-06-19

Family

ID=44913251

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800496321A Pending CN103167873A (zh) 2010-10-27 2011-10-25 治疗眼血管疾病的给药方案

Country Status (12)

Country Link
US (1) US20130197016A1 (enExample)
EP (1) EP2632458B1 (enExample)
JP (1) JP5934229B2 (enExample)
KR (1) KR20140008303A (enExample)
CN (1) CN103167873A (enExample)
AU (1) AU2011322597B2 (enExample)
BR (1) BR112013009701A2 (enExample)
CA (1) CA2814439A1 (enExample)
EA (1) EA022873B1 (enExample)
ES (1) ES2547145T3 (enExample)
MX (1) MX2013004782A (enExample)
WO (1) WO2012055884A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
US9353122B2 (en) * 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US10174006B2 (en) 2013-06-06 2019-01-08 Novartis Ag Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
EP3570093B1 (en) 2013-11-15 2021-09-15 Tangible Science, Inc. Contact lens with a hydrophilic layer
JPWO2015147204A1 (ja) * 2014-03-27 2017-04-13 国立大学法人京都大学 血管新生増殖因子を阻害する医薬組成物
CN107206119B (zh) 2014-12-09 2021-01-29 实体科学公司 具有生物相容性层的医疗设备涂层
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021067823A2 (en) * 2019-10-05 2021-04-08 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
EP2380572A1 (en) 2005-11-29 2011-10-26 Glaxosmithkline LLC Cancer treatment method
CA2666709A1 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BENJAMIN P,ET AL.: "A review of clinical trials of anti-VEGF agents for diabetic retinopathy", 《GRAEFES ARCH CLIN EXP OPHTHALMOL》 *
HELEN KOURLAS,ET AL.: "Pegaptanib Sodium for the Treatment of Neovascular Age-Related Macular Degeneration: A Review", 《CLINICAL THERAPEUTICS》 *
KYOICHI TAKAHASHI,ET AL.: "Suppression and Regression of Choroidal Neovascularization by the Multitargeted Kinase Inhibitor Pazopanib", 《ARCH OPHTHALMOL》 *
ZIAD F.BASHSHUR,ET AL.: "Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration", 《AM J OPHTHALMOL》 *

Also Published As

Publication number Publication date
BR112013009701A2 (pt) 2016-07-19
EP2632458A1 (en) 2013-09-04
JP2013540791A (ja) 2013-11-07
US20130197016A1 (en) 2013-08-01
JP5934229B2 (ja) 2016-06-15
AU2011322597A1 (en) 2013-05-02
EA022873B1 (ru) 2016-03-31
AU2011322597B2 (en) 2015-09-10
EP2632458B1 (en) 2015-08-12
MX2013004782A (es) 2013-06-03
WO2012055884A1 (en) 2012-05-03
ES2547145T3 (es) 2015-10-02
KR20140008303A (ko) 2014-01-21
CA2814439A1 (en) 2012-05-03
EA201390618A1 (ru) 2013-08-30

Similar Documents

Publication Publication Date Title
AU2024200946B2 (en) Compositions and methods for treating pterygium
EP2632458B1 (en) Dosing regimes for the treatment of ocular vascular disease
RS63136B9 (sr) Lekoviti sastav koji sadrži tivozanib
JP6466504B2 (ja) 長時間の眼圧低下効果を有するアルファ−２アドレナリンアゴニスト
US20130012531A1 (en) Treatment method
TW202216119A (zh) 眼用活性醫藥成分輸送的固態環糊精複合物製備
US20250213541A1 (en) Suspension compositions of multi-target inhibitors
WO2010117077A1 (ja) シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤
JP2011144111A (ja) 軸性近視の予防または治療剤
CA2897949A1 (en) Topical aqueous ophthalmic compositions containing a 1h-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease
HK40101374A (en) Compositions and methods for treating pterygium
JP2009079041A (ja) リチウム塩を有効成分として含有する後眼部疾患の治療又は予防剤
TW202038928A (zh) 多目標抑製劑的懸浮液組合物
US20130210876A1 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
HK1253895B (en) Compositions and methods for treating pterygium
CN106456641A (zh) 眼后段疾病的预防或治疗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130619